Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer
A Study to Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry of ZA-001, an Alpha-particle-emitting (At211) Radiopharmaceutical, in metastatic castration resistant prostate cancer
Metastatic Prostate Cancer
DRUG: ZA-001
The absorbed radiation doses (Gray [Gy] /Megabecquerel [MBq] )for whole body and organ, SPECT/CT will be scanned following administration of the ZA-001, 24 hours|Adverse Event, Number of participants with Adverse Events as a measure of safety and tolerability, 1 week
A Study to Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry of ZA-001, an Alpha-particle-emitting (At211) Radiopharmaceutical, in metastatic castration resistant prostate cancer